Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib drug-drug interaction study
NCT07235748Phase 1Completed
- Sponsor
- Servier
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorasidenib in glioma, sponsored by Servier. Primary endpoints: Maximum concentration at 29 days, Area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration at 29 days and 6 more. Started Oct 2025; status: completed.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07235748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235748.